Enabling precision medicine

Olink at a glance

Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This makes research possible, which previously could not be done, at lower unit costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease, which is key to improving treatment and patient outcomes across many disease areas.

Key developments in 2020

In June 2020, Olink launched Explore, a new offering where its PEA technology is applied on Next-Generation Sequencing platforms, enabling greater significantly improved scale and higher throughput than ever before. This offering further strengthens Olink’s market position in high plex proteomics and enables its customers to continue making great leaps in understanding of real-time human biology.

Despite Covid-19, Olink has driven a ramp-up of the organization, increasing headcount by 60% and expect to continue its growth journey over the coming years. While Covid-19 adversely impacted the revenue growth for 2020 as customers had issues accessing their labs, Olink has continued to build a very strong pipeline and positive momentum in the market.